Xin Lang Ji Jin·2025-07-15 12:49Market Overview - The market experienced fluctuations with mixed index performances, where the Shanghai Composite Index fell by 0.42%, while the Shenzhen Component Index rose by 0.56% and the ChiNext Index increased by 1.73% [1] - The total trading volume in the Shanghai and Shenzhen markets reached 1.61 trillion yuan, an increase of 153.3 billion yuan compared to the previous trading day [1] AI Sector Performance - AI-related stocks, including optical modules, liquid-cooled servers, and AI applications, led the market gains [1] - The China Securities Index reported that the AI-focused ETF from Guotai (159388) surged by 6.97%, and the communication ETF (515880) rose by 6.14%, both reaching historical highs [3] Nvidia's Market Impact - Nvidia announced it received permission from the Trump administration to resume sales of the "special version" H20 chips to China, following a meeting between CEO Jensen Huang and President Trump [5] - The introduction of a new GPU based on the Blackwell architecture, compliant with U.S. export regulations, is expected to enhance investments in AI infrastructure [5][7] - The easing of U.S.-China trade tensions since June has alleviated concerns over chip shortages in China, benefiting AI data centers and related sectors [5][6] Optical Module Sector Growth - New Yi Sheng, a leader in optical modules, projected a significant profit increase for the first half of 2025, estimating a net profit of 3.7 billion to 4.2 billion yuan, representing a year-on-year growth of 327.68% to 385.47% [6] - The North American cloud service providers' capital expenditure reached 77.1 billion USD in Q1 2025, a 59% increase, indicating a strong demand for optical modules [6] Innovation Drug Sector Developments - The innovation drug ETF from Guotai (517110) rose by 1.74%, supported by favorable policies from the National Healthcare Security Administration and the National Health Commission [9] - The domestic innovation drug market is expected to see significant growth, with a projected increase in the number of innovative drugs entering clinical trials [9][10] - AI is anticipated to enhance the pharmaceutical industry across various stages, including drug development and production [10]